These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

526 related items for PubMed ID: 21219979

  • 1. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial.
    Plennevaux E, Blatter M, Cornish MJ, Go K, Kirby D, Wali M, Reeves-Hoché MK, Denis M.
    Vaccine; 2011 Feb 11; 29(8):1569-75. PubMed ID: 21219979
    [Abstract] [Full Text] [Related]

  • 2. Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial.
    Oh CE, Lee J, Kang JH, Hong YJ, Kim YK, Cheong HJ, Ahn YJ, Kim SH, Lee HJ.
    Vaccine; 2010 Aug 16; 28(36):5857-63. PubMed ID: 20600483
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents.
    Lu CY, Shao PL, Chang LY, Huang YC, Chiu CH, Hsieh YC, Lin TY, Huang LM.
    Vaccine; 2010 Aug 16; 28(36):5864-70. PubMed ID: 20600484
    [Abstract] [Full Text] [Related]

  • 4. A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza.
    Kung HC, Huang KC, Kao TM, Lee YC, Chang FY, Wang NC, Liu YC, Lee WS, Liu HJ, Chen CI, Chen CH, Huang LM, Hsieh SM.
    Vaccine; 2010 Oct 21; 28(45):7337-43. PubMed ID: 20817013
    [Abstract] [Full Text] [Related]

  • 5. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 21; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 6. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.
    Pediatrics; 2006 Sep 21; 118(3):e579-85. PubMed ID: 16950949
    [Abstract] [Full Text] [Related]

  • 7. Response to a monovalent 2009 influenza A (H1N1) vaccine.
    Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, Basser RL.
    N Engl J Med; 2009 Dec 17; 361(25):2405-13. PubMed ID: 19745216
    [Abstract] [Full Text] [Related]

  • 8. Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children.
    Block SL, Ruiz-Palacios GM, Guerrero ML, Beygo J, Sales V, Holmes SJ.
    Pediatr Infect Dis J; 2012 Jul 17; 31(7):e92-8. PubMed ID: 22481427
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity of inactivated 2009 H1N1 influenza vaccine in pediatric liver transplant recipients.
    Torii Y, Kimura H, Ochi N, Kaneko K, Ando H, Kiuchi T, Ito Y.
    Vaccine; 2011 Jun 06; 29(25):4187-9. PubMed ID: 21513762
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
    Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM.
    Vaccine; 2010 Feb 17; 28(7):1740-5. PubMed ID: 20034605
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
    King JC, Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P.
    Vaccine; 2009 Nov 05; 27(47):6589-94. PubMed ID: 19716456
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
    Avila Aguero ML, Soriano-Fallas A, Umaña-Sauma MA, Ulloa-Gutierrez R, Arnoux S.
    Medicina (B Aires); 2007 Nov 05; 67(4):351-9. PubMed ID: 17891930
    [Abstract] [Full Text] [Related]

  • 13. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
    Nassim C, Christensen S, Henry D, Holmes S, Hohenboken M, Kanesa-Thasan N.
    Pediatr Infect Dis J; 2012 Apr 05; 31(4):e59-65. PubMed ID: 22418661
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea.
    Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, Park DW, Wie SH, Kim WJ.
    Vaccine; 2011 Jan 10; 29(3):523-7. PubMed ID: 21055502
    [Abstract] [Full Text] [Related]

  • 15. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems.
    Precioso AR, Miraglia JL, Campos LM, Goulart AC, Timenetsky Mdo C, Cardoso MR, Luna E, Mondini G, Guedes Jda S, Raw I.
    Vaccine; 2011 Nov 08; 29(48):8974-81. PubMed ID: 21945258
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.
    Nolan T, McVernon J, Skeljo M, Richmond P, Wadia U, Lambert S, Nissen M, Marshall H, Booy R, Heron L, Hartel G, Lai M, Basser R, Gittleson C, Greenberg M.
    JAMA; 2010 Jan 06; 303(1):37-46. PubMed ID: 20026597
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and safety of a 2009 pandemic influenza A (H1N1) monovalent vaccine in Chinese infants aged 6-35 months: a randomized, double-blind, controlled phase I clinical trial.
    Li YP, Li W, Liang XF, Liu Y, Huang XC, Li CG, Li RC, Wang JZ, Wang HQ, Yin WD.
    Influenza Other Respir Viruses; 2013 Nov 06; 7(6):1297-307. PubMed ID: 23134570
    [Abstract] [Full Text] [Related]

  • 18. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
    Englund JA, Walter E, Black S, Blatter M, Nyberg J, Ruben FL, Decker MD, GRC28 Study Team.
    Pediatr Infect Dis J; 2010 Feb 06; 29(2):105-10. PubMed ID: 19934787
    [Abstract] [Full Text] [Related]

  • 19. A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory.
    Loew-Baselli A, Pavlova BG, Fritsch S, Poellabauer EM, Draxler W, Kistner O, Behre U, Angermayr R, Neugebauer J, Kirsten K, Förster-Waldl E, Koellges R, Ehrlich HJ, Barrett PN.
    Vaccine; 2012 Sep 07; 30(41):5956-66. PubMed ID: 22846396
    [Abstract] [Full Text] [Related]

  • 20. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
    Nolan T, Richmond PC, Formica NT, Höschler K, Skeljo MV, Stoney T, McVernon J, Hartel G, Sawlwin DC, Bennet J, Ryan D, Basser RL, Zambon MC.
    Vaccine; 2008 Nov 25; 26(50):6383-91. PubMed ID: 18801398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.